# CLL2-BZAG (NCT04515238)

> Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04515238
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphoid Leukemia
- Interventions: Bendamustine; Obinutuzumab; Zanubrutinib; Venetoclax
- Enrollment: 42
- Primary outcome: Negativity rate of minimal residual disease (MRD) in peripheral blood (PB) measured by multi-color flow cytometry

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 2
- YouTube: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cll2-bzag-nct04515238